Materials and methods for treatment of autosomal dominant retinitis pigmentosa

Patent metadata

Field	Value
Publication number	US-12247201-B2
Application number	US-202016838545-A
Country	US
Kind code	B2
Filing date	Apr 2, 2020
Priority date	Nov 21, 2017
Publication date	Mar 11, 2025
Grant date	Mar 11, 2025

Abstract

The present application provides materials and methods for treating a patient with autosomal dominant RP, both ex vivo and in vivo; materials and methods for editing a RHO gene in a human cell; and materials and methods for editing a P23H mutation in a RHO gene in a human cell. In addition, the present application provides one or more gRNAs or sgRNAs for editing a RHO gene; one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene. The present application provides a therapeutic for treating a patient with autosomal dominant RP. The present application provides a kit for treating a patient with autosomal dominant RP. In addition, the present application provides a self-inactivating CRISPR-Cas system.

First claim

What is claimed is:

1. A method for editing a P23H mutation within a RHO gene of a cell, the method comprising, contacting the cell with a self-inactivating CRISPR-Cas system comprising:
(a) a first segment comprising a nucleotide sequence that encodes an S. aureus Cas9 polypeptide;
(b) a second segment comprising a nucleotide sequence that encodes a guide RNA (gRNA) or a single-molecule guide RNA (sgRNA), wherein the gRNA or the sgRNA comprises SEQ ID NO: 5290 or 5291; and
(c) one or more third segments comprising a self-inactivating (SIN) site, wherein the SIN site is:
(i) a 5′ SIN site located upstream of the nucleotide sequence the encodes the Cas9 polypeptide and downstream of a SV40 nuclear localization signal (NLS);
(ii) a 5′ SIN site located upstream of the nucleotide sequence the encodes the Cas9 polypeptide and upstream of a SV40 NLS within a 5′UTR; or
(iii) a 3′ SIN site located within a naturally occurring or chimeric inserted intron located within the nucleotide sequence the encodes the Cas9 polypeptide,

wherein the gRNA or sgRNA is complementary to the SIN site.

2. The method of claim 1 , wherein the 5′ SIN site comprises SEQ ID NO: 5300 or 5301, and wherein the 3′ SIN site comprises SEQ ID NO: 5289 or 5281.

3. The method of claim 1 , wherein the SIN site comprises a protospacer adjacent motif (PAM), and wherein the PAM is NNGRRT.

4. The method of claim 1 , wherein the first segment further comprises a start codon, a stop codon, and a poly (A) termination site.

5. The method of claim 1 , wherein the first segment and the third segment are provided together in a first vector, and the second segment is provided in a second vector.

6. The method of claim 5 , wherein the first vector comprises SEQ ID NO: 5341 or 5342, and wherein the second vector comprises SEQ ID NO: 5339 or 5340.

7. The method of claim 5 , wherein the first vector and the second vector are adeno-associated virus (AAV) vectors.

8. The method of claim 7 , wherein the AAV vectors are AAV5 serotype capsid vectors.

9. The method of claim 1 , wherein the first segment, second segment, and third segment are provided together in a vector.

10. The method of claim 9 , wherein the vector is an AAV vector.

11. The method of claim 10 , wherein the AAV vector is an AAV5 serotype capsid vector.

12. The method of claim 1 , wherein the gRNA or the sgRNA is complementary to the nucleotide sequence of the SIN site except for in at least one location.

13. The method of claim 1 , wherein a nucleic acid sequence encoding a promoter is operably linked to the first segment.

14. The method of claim 13 , wherein the promoter is a spatially-restricted promoter, bidirectional promoter, or an inducible promoter.

15. The method of claim 14 , wherein the spatially-restricted promoter is selected from the group consisting of: any tissue or cell type specific promoter, a hepatocyte-specific promoter, a neuron-specific promoter, an adipocyte-specific promoter, a cardiomyocyte-specific promoter, a skeletal muscle-specific promoter, lung progenitor cell specific promoter, a photoreceptor-specific promoter, and a retinal pigment epithelial (RPE) selective promoter.

16. A method for treating a patient with a P23H mutation within a RHO gene, the method comprising, administering a self-inactivating CRISPR-Cas system comprising:
(a) a first segment comprising a nucleotide sequence that encodes an S. aureus Cas9 polypeptide;
(b) a second segment comprising a nucleotide sequence that encodes a guide RNA (gRNA) or a single-molecule guide RNA (sgRNA), wherein the gRNA or the sgRNA comprises SEQ ID NO: 5290 or 5291; and
(c) one or more third segments comprising a self-inactivating (SIN) site, wherein the SIN site is:
(i) a 5′ SIN site located upstream of the nucleotide sequence the encodes the Cas9 polypeptide and downstream of a SV40 nuclear localization signal (NLS);
(ii) a 5′ SIN site located upstream of the nucleotide sequence the encodes the Cas9 polypeptide and upstream of a SV40 NLS within a 5′UTR; or
(iii) a 3′ SIN site located within a naturally occurring or chimeric inserted intron located within the nucleotide sequence the encodes the Cas9 polypeptide,

wherein the gRNA or sgRNA is complementary to the SIN site.

17. The method of claim 16 , wherein the 5′ SIN site comprises SEQ ID NO: 5300 or 5301, and wherein the 3′ SIN site comprises SEQ ID NO: 5289 or 5281.

18. The method of claim 16 , wherein the SIN site comprises a protospacer adjacent motif (PAM), and wherein the PAM is NNGRRT.

19. The method of claim 16 , wherein the first segment further comprises a start codon, a stop codon, and a poly (A) termination site.

20. The method of claim 16 , wherein the first segment and the third segment are provided together in a first vector, and the second segment is provided in a second vector.

21. The method of claim 20 , wherein the first vector comprises SEQ ID NO: 5341 or 5342, and wherein the second vector comprises SEQ ID NO: 5339 or 5340.

22. The method of claim 20 , wherein the first vector and the second vector are adeno-associated virus (AAV) vectors.

23. The method of claim 22 , wherein the AAV vectors are AAV5 serotype capsid vectors.

24. The method of claim 16 , wherein the first segment, second segment, and third segment are provided together in a vector.

25. The method of claim 24 , wherein the vector is an AAV vector.

26. The method of claim 25 , wherein the AAV vector is an AAV5 serotype capsid vector.

27. The method of claim 16 , wherein the gRNA or the sgRNA is complementary to the nucleotide sequence of the SIN site except for in at least one location.

28. The method of claim 16 , wherein a nucleic acid sequence encoding a promoter is operably linked to the first segment.

29. The method of claim 28 , wherein the promoter is a spatially-restricted promoter, bidirectional promoter, or an inducible promoter.

30. The method of claim 29 , wherein the spatially-restricted promoter is selected from the group consisting of a photoreceptor-specific promoter and a retinal pigment epithelial (RPE) selective promoter.

Assignees

• Crispr Therapeutics Ag
• Bayer Healthcare Llc

Inventors

• Kantardzhieva Albena
• Noma Akiko
• Scaria Abraham
• Takeuchi Ryo

Classifications

• A61K38/465

  acting on ester bonds (3.1), e.g. lipases, ribonucleases · CPC title

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title

• C12N15/1138

  against receptors or cell surface proteins · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• C12N2800/80

  Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites · CPC title